Navigation Links
Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients
Date:6/2/2008

.

About Genzyme

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 10,000 employees in locations spanning the globe and 2007 revenues of $3.8 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation.

With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, cardiovascular disease, and other areas of unmet medical need.

This press release contains forward-looking statements, including statements regarding the potential administration, dosing and therapeutic benefit of Clolar in various cancer indications; the expected results of the data generated from the Clolar clinical trials; and the requirements and plans for regulatory filings and approvals for Clolar in additional indications. These risks and uncertainties include, among others, the timing of discussions with the FDA regarding clinical studies and approval of Clolar in additional indications; the timing and content of decisions by the FDA related to clinical trials and approval of Clolar in additional indications; the actual efficacy and safety of Clolar for the indications in which it is being tested; and the risks and uncertainties described in reports filed by Genzyme with the U.S. Securities and Exchange Commission, including without limitation t
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Genomic Health Announces Preliminary Results From a Study of Oncotype DX(TM) in Node-Positive Breast Cancer Patients
3. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
4. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
5. Pharmion and MethylGene Report Preliminary MGCD0103 Clinical Data at the 2007 AACR-NCI-EORTC International Conference
6. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
7. Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) at the American Society of Hematology Meeting
8. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
9. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
10. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
11. A Functional Immune System Can Be Derived From Embryonic Stem Cells, Preliminary Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008)...irl with Hypophosphatasia Treated With ENB-0040 at...nnipeg , , MONTREAL, Dec. 1 ...ny focused on developing novel therapeutics for se...st infant patient in its clinical program for hypo...zyme Replacement Therapy (ERT) with ENB-0040 for t...
(Date:12/1/2008)...ISTGARD, Denmark, December 1 /PRNewswire-FirstCall...007 with the intent to procure an MVA-based,thir...vernment Services,Canada, on behalf of the Canadi...contract to Bavarian Nordic for the delivery of IM...d to use IMVAMUNE(R) as part of the,country,s bio...
(Date:11/30/2008)... , CHICAGO, Dec. 1 O...cerebral blood flow and a greater number of small ...presented today at the annual meeting of the Radio... The study, conducted at the University of Nort... compare brain scans of older adults who exercise ...
(Date:11/27/2008)...udy finds the majority of acute lymphoblastic leuk...nt at the time of diagnosis , , MEMPHIS, Te... at St. Jude Children,s Research Hospital have ide...cells of children with acute lymphoblastic leukemi...athway to designing treatments for ALL relapse in ...
Breaking Medicine Technology:Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 2Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 3Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 4Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 5The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness 2The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness 3Exercise Helps Prevent Age-Related Brain Changes in Older Adults 2Exercise Helps Prevent Age-Related Brain Changes in Older Adults 3St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 2St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 3AMDL Inc Closes Private Placement of Convertible Notes 7718 1AMDL Inc Closes Private Placement of Convertible Notes 7718 2AMDL Inc Closes Private Placement of Convertible Notes 7718 3AMDL Inc Closes Private Placement of Convertible Notes 7718 4Simulations help explain fast water transport in nanotubes 4912 1Simulations help explain fast water transport in nanotubes 4912 2Canadian Company Sued for Defrauding Thousands of U S Consumers of Dietary Supplements 26497 1Canadian Company Sued for Defrauding Thousands of U S Consumers of Dietary Supplements 26497 2Joint Commission Urges Patients to Speak Up About Pain 3071 1Joint Commission Urges Patients to Speak Up About Pain 3071 2Joint Commission Urges Patients to Speak Up About Pain 3071 3
...ALTHAM, Mass.--(BUSINESS WIRE)--Apr 17, 2007 - Adn...esentation of the abstract,"CT-322: A specific VEG...ity in preclinical tumor models comparable to pan-...inib and sorafenib" at the,American Association fo...s Angeles, CA. The lead author is Irvith Carvajal,...
...SUNNYVALE, Calif. and LOS ANGELES, April 18, 2007,...y announced data,from two preclinical studies, one...histone deacetylase (HDAC) inhibitor and,another d...its,Bruton,s tyrosine kinase (BTK) inhibitor compo...ciation for Cancer Research (AACR),2007 Annual Mee...
Other Medicine Technology:Adnexus Therapeutics Announces Presentation at the American,Association for Cancer Research (AACR) on Clinical Product,Candidate, CT-322 2Adnexus Therapeutics Announces Presentation at the American,Association for Cancer Research (AACR) on Clinical Product,Candidate, CT-322 3Adnexus Therapeutics Announces Presentation at the American,Association for Cancer Research (AACR) on Clinical Product,Candidate, CT-322 4Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC,Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with,Bruton's Tyrosine Kinase Inhibitors 2Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC,Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with,Bruton's Tyrosine Kinase Inhibitors 3Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC,Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with,Bruton's Tyrosine Kinase Inhibitors 4Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC,Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with,Bruton's Tyrosine Kinase Inhibitors 5
(Date:12/1/2008)...scription meds, supplements can also trigger acute...ec. 1 (HealthDay News) -- Antibiotics are the sing... drug-induced liver injury (DILI), researchers say... of cases of acute liver failure in the United Sta...te liver failure. , DILI is caused by a wide ra...
(Date:12/1/2008)...al December push wraps up successful disaster reli...ire-USNewswire/ -- The American Red Cross is askin...s by raising $30 million in 30 days. This holiday ...illion goal for the Red Cross Campaign for Disaste...$70 million since its launch in September, and the...
(Date:12/1/2008)...XANDRIA, Va., Dec. 1 To...act, nearly 7,000 people die each day due to HIV... day of awareness and outreach to help people worl... theme for World AIDS Day 2008 is You Can Make a...ringing people together to talk about HIV as well ...
(Date:12/1/2008)... DIEGO, Dec. 1 SpectraSc...go based medical device company, today,announced ... Optical Biopsy,System for Tissue Diagnosis. , ...is patent is important to,the Company,s optical b... the,areas of tissue surveillance, characterizati...
Breaking Medicine News(10 mins):Health News:Antibiotics Largest Cause of Drug-Induced Liver Damage 2Health News:Red Cross Asks America to Help Raise $30 Million in 30 Days 2Health News:Red Cross Asks America to Help Raise $30 Million in 30 Days 3Health News:In Support of World AIDS Day, FHSSA Announces New Partnerships That Include the First In-Country Partnerships in Namibia and The Gambia 2Health News:SpectraScience Awarded European Patent for Its Optical Biopsy System for Tissue Diagnosis 2
...mpany, has acquired Innovation Sports, Inc., a U.S...The acquisition of Innovation Sports comes on the ...Medical in the U.S., and the December 2005 acquisi...ese acquisitions, and its 2003 acquisition of Gene...
...ster of the Indian State of Bihar has been given t...tish Kumar, the State’s Chief Minister is reported...m the city of Patna. Sources close to Nitish Kum...ve the law and order situation in the state, but e...
...e Cancer Center – Arthur G. James Cancer Hospital ...nd a tumor suppressor gene that could be of vital ...ancers as well as lung cancer. //Their study shows...he development of the aforementioned cancers.<...
...staff, it has been proposed to extend the Medicare... currently played by nurses, podiatrist surgeons a...her extended to accomodate them into vacant postit...rom doctors and other health professionals. The pr...
Other Medicine News:Health News:Ossur Acquires the U.S. Orthopaedics Company 2Health News:Unusual Tumor-Suppressor Gene Switches Off in Lung Cancer 2Health News:Additional Responsiblities To Be Taken Up By Allied Healthcare Professionals 2
The Endotrac™ System includes an Obturator, Slotted Cannula, Synovial Elevator, Ligament Probe, Ligament Rasp, Blade Handle, two Retractors and sterilizable tray. The Endotrac&trade.
Low-profile hand-held instruments.
The BioPro Basal Thumb joint is manufactured from Cobalt Chrome and is used to replace the Trapeziometacarpal joint.
Anatomic implant shape and easy-to use instrumentation promote implant alignment, stability, and restored joint kinematics.
Medicine Products: